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Converting enzyme inhibition causes hypocitraturia independent
of acidosis or hypokalemia.
Background. Angiotensin II stimulates the proximal tubular
Na/H antiporter and increases proximal tubular cell pH. Because
intracellular pH may affect urinary citrate excretion and enzymes
responsible for renal citrate metabolism, the present studies
examined the effect of enalapril, an angiotensin converting en-
zyme inhibitor, on the activity of renal cortical ATP citrate lyase
and urinary citrate excretion.
Methods. Enalapril was given to rats (15 mg/kg/day) for seven
days and to humans (10 mg twice daily) for 10 days. Blood and
24-hour urine samples were obtained in both groups. Renal
cortical tissue from rats was analyzed for enzyme activity.
Results. In rats, enalapril decreased urinary citrate excretion by
88%. The change in urinary citrate was not associated with a
difference in plasma pH, bicarbonate nor potassium concentra-
tion. However, similar to metabolic acidosis and hypokalemia,
enalapril caused a 42% increase in renal cortical ATP citrate lyase
activity. When given to humans, enalapril significantly decreased
urinary citrate excretion and urine citrate concentration by 12%
and 16%, respectively, without affecting plasma pH or electro-
lytes.
Conclusions. Enalapril decreases urinary citrate in rats and
humans. This is due, at least in part, to increases in cytosolic
citrate metabolism through ATP citrate lyase in rats similar to that
seen with chronic metabolic acidosis and hypokalemia. The effects
of enalapril on urinary citrate and renal cortical ATP citrate lyase
occur independently of acidosis or hypokalemia but may be due to
intracellular acidosis that is common to all three conditions.
Urinary citrate is freely filtered in the glomerulus and
then reabsorbed in the proximal tubule [1]. Hypocitraturia,
an important cause of kidney stones [2], occurs by an
increase in proximal tubule reabsorption [3]. Chronic met-
abolic acidosis (CMA) [4] or hypokalemia [5] causes hy-
pocitraturia with concomitant adaptive increases in proxi-
mal tubular apical membrane Na-citrate cotransporter
(NaDC-1) activity [6, 7], and protein and mRNA abun-
dance [8]. Once reabsorbed, citrate is metabolized either in
the mitochondria through the tricarboxylic acid cycle [9] or
in the cytosol through adenosine 59-triphosphate (ATP)
citrate lyase, which cleaves citrate to acetyl CoA and
oxaloacetate [10]. The oxaloacetate enters the gluconeo-
genic pathway via an increase in phosphoenolpyruvate
carboxykinase observed in CMA [11]. Since both CMA and
hypokalemia decrease renal cortical intracellular pH (pHi)
[12], these adaptations are thought to occur through a
change in pHi [1, 3].
Angiotensin II (Ang II) increases pHi by activating an
amiloride-sensitive apical membrane Na/H antiporter in
the proximal tubule [13]. Angiotensin converting enzyme
inhibitors, by decreasing Ang II production, may decrease
pHi and cause hypocitraturia. To determine if inhibiting
Ang II production could affect urinary citrate excretion, we
administered enalapril first to rats and then humans. The
results demonstrate that this therapy decreases urinary
citrate excretion in both species. In rats, the change in
urinary citrate excretion is associated with an increase in
renal cortical ATP citrate lyase activity, similar to that seen
in rats with CMA and hypokalemia [10].
METHODS
Animals
Male Sprague-Dawley rats, weighing 200 to 220 grams,
were housed in individual metabolic cages and allowed to
acclimate on a synthetic diet ad libitum for three days. The
diet consisted of (in g) 180 casein (ICN Biomedicals, Inc.,
Costa Mesa, CA, USA), 200 cornstarch, 500 sucrose, 35
corn oil, 35 peanut oil, 10 CaHPO4, 6 MgSO4, 6 NaCl, 8.3
K2HPO4 and 10 vitamin fortification mixture (ICN Bio-
medicals, Inc.). Animals were allowed free access to water
during the acclimation and experimental periods.
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Experimental protocol
After three days of acclimation, all rats were weighed
and experimental rats received powdered enalapril (gift
from Merck & Co., West Point, PA, USA) 15 mg/kg mixed
into the control diet. They were fed a maximum of 20 g diet
daily for one week. Control rats were pair-fed with only the
control diet. On the sixth day of the experimental period, a
24-hour urine collection for total volume, sodium, potas-
sium, chloride, creatinine and citrate was obtained in the
presence of thymol to prevent bacterial digestion of the
citrate [14]. On the seventh day, rats were anesthetized with
100 mg/kg of Inactin (Promonta, Germany) intraperitone-
ally. Blood was obtained by aortic puncture for sodium,
potassium, chloride, bicarbonate, pCO2, pH, glucose and
creatinine.
Tissue preparation
Kidneys were harvested, decapsulated and placed in
ice-cold homogenization buffer containing (in mM), 300
sucrose, 5 K2HPO4, 1 EDTA, 10 NaCitrate at pH 7.4.
Kidneys were then placed on a petri dish over ice and the
medulla dissected away. Cortical tissue was homogenized at
medium speed with a loose-fitting Potter-Elvehjem in 10 3
volume homogenization solution with 1 mg/ml phenyl-
methylsulfonyl fluoride, 2 mg/ml aprotinin and 7 mM di-
thiotheitol added at harvest. Solid material was removed by
centrifugation at 48,000 g and the supernatant was placed
at 220°C overnight.
Measurement of ATP citrate lyase activity
Adenosine 59-triphosphate (ATP) citrate lyase activity
was measured using the hydroxamate assay in which hy-
droxylamine is deaminated and acetylated [15]. The assay
was performed as previously published with generation of
acetylhydroxamate measured spectrophotometrically [10].
Due to high intrinsic NADH oxidase activity in the kidney,
a malate dehydrogenase-linked assay could not be used
[10]. Protein concentration was determined using a bicin-
choninic acid protein assay kit (Pierce Chemical Co., Rock-
ford, IL, USA) with bovine serum albumin as a standard.
Human study
Ten normal adult volunteers (6 females and 4 males, ages
24 to 43) participated in the study after written consent was
obtained. They were free of heart disease, hypertension,
edema, hypokalemia, urolithiasis, chronic diarrheal states,
diabetes mellitus, and renal disease. Normal subjects in-
volved in daily physical exercise were excluded. Subjects
receiving medication such as converting enzyme inhibitors,
and non-steroidal anti-inflammatory drugs were also ex-
cluded.
The subjects participated in 13 days of study that con-
sisted of two three-day phases. During those phases on days
1 to 3 (baseline) and 10 to 13 (enalapril), subjects ingested
a frozen metabolic diet with a daily composition of 400 mg
calcium, 800 mg phosphorus, 100 mEq sodium, 60 mEq
potassium, and 3 liters of distilled water. For days 4 to 10,
subjects were instructed by a dietician to receive a limited
calcium and sodium diet. After completion of the baseline
phase on day 4, subjects began oral enalapril 10 mg
(Vasotec®; Merck & Co) twice a day for 10 days.
After two days of stabilization on the frozen metabolic
diet in each phase of the study, the subjects collected urine
for 24 hours under mineral oil for total volume, pH,
sodium, potassium, ammonium, citrate, uric acid, oxalate,
calcium and creatinine. On the morning of days 4 and 14,
arterialized venous blood was obtained for sodium, potas-
sium, chloride, glucose, total CO2, pH, pCO2, BUN, creat-
inine, uric acid, cholesterol, calcium and phosphorus [16].
Plasma and urine measurements
In the rat study, creatinine, plasma and urine electro-
lytes, were measured using a Beckman Astra-7 (Fullerton,
CA, USA) analyzer. Plasma pH, pCO2 and bicarbonate
were determined using an Instrumental Laboratory (Lex-
ington, MA, USA) blood gas analyzer. Citrate was mea-
sured using a commercially available kit (Boehringer
Mannheim, Indianapolis, IN, USA).
For the human study, calcium was determined by atomic
absorption spectrophotometry. Serum electrolytes, creati-
nine, BUN and glucose were measured using a Beckman
Astra-7 analyzer. Serum pH and pCO2 were analyzed by
the CIBA-Corning (Medfield, MA, USA) blood gas system.
Urinary sodium and potassium were determined by flame
photometry, and creatinine and ammonium by colorimetry.
Urinary pH was measured by electrode pH meter, uric acid
by uricase method, oxalate by ion chromatography, and
phosphorus by the method of Fiske and Subbarow [17].
Urinary citrate was determined by measuring the genera-
tion of phenylhydrazone from phenylhydrazine [18].
All results are expressed as mean 6 SEM. Paired Stu-
dent’s t-test (Sigma Stat, Jandel Scientific, San Rafael, CA,
USA) was used for comparison of results between control
and experimental groups in the rat study and between
baseline and enalapril in the human study. Sigma Chemical
Co. (St. Louis, MO, USA) supplied all chemicals unless
otherwise stated.
RESULTS
Twenty-six rats were studied (13 in each group) and
consumed an average of 83% of the diet. Rats fed enalapril
gained on average 30 grams with control rats gaining on
average 25 grams during the experimental period (NS).
Urine volume, electrolytes, and creatinine are listed in
Table 1. Total sodium, chloride, and creatinine excretion
were similar between control and experimental groups.
Enalapril-fed rats excreted more urine (15.3 vs. 7.5 ml/day;
P , 0.005) and potassium (0.60 vs. 0.43 mEq/day; P ,
0.05). Plasma pH, electrolytes, glucose and creatinine are
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listed in Table 2. All values were similar between the
groups. Figure 1 reveals that both urinary citrate excretion
and fractional excretion of citrate were decreased in rats
given enalapril (0.34 vs. 2.80 mg/day and 0.66 vs. 4.10,
respectively; P , 0.005 for both).
In animals with similar decreases in urinary citrate, 98%
in CMA and 95% in hypokalemia, there is an increase in
renal cortical citrate ATP citrate lyase [10]. To determine
whether ATP citrate lyase activity increases in enalapril-
induced hypocitraturia, we measured the activity of this
enzyme in renal cortex. Figure 2 demonstrates that enala-
pril-fed rats exhibited a 42% increase in renal cortical ATP
citrate lyase activity (in nmoles acetylhydroxamate forma-
tion/30 min/mg protein; 63.3 6 7.2 vs. 44.6 6 5.2; P ,
0.005).
To examine the effect of enalapril on humans, we placed
normal volunteers on a frozen metabolic diet and measured
blood and urine samples before and after 10 days of
enalapril. Results (Tables 3 and 4) reveal a small but
consistent decrease in serum cholesterol following enala-
pril. Furthermore, as can be seen in Table 3, urinary
sodium and potassium excretions matched the dietary
composition, indicating the subjects were in balance and
had good compliance with the prescribed diet. Figure 3
shows a small but significant decrease in both urinary
citrate excretion (638 6 82 vs. 560 6 72 mg/day, P , 0.1)
and concentration (327 6 78 vs. 276 6 61 mg/liter, P ,
0.05) after enalapril.
DISCUSSION
Angiotensin converting enzyme inhibition by enalapril
caused hypocitraturia in rats. In that plasma concentrations
of citrate and creatinine did not change, it is unlikely that
the filtered load of citrate changed sufficiently to explain
the hypocitraturia. Thus, in this model, as in acidosis and
hypokalemia, enhanced tubular citrate reabsorption im-
putes the hypocitraturia. The degree of hypocitraturia with
enalapril was similar to that seen in animals with metabolic
acidosis or hypokalemia [10]. However, in contrast to these
animals, enalapril-fed rats had no significant decrease in
plasma pH, bicarbonate or potassium when compared with
controls.
The higher urine volume seen in rats may be attributed
to enalapril’s inability to cross the blood-brain barrier and
to block angiotensin II (Ang II) production in the central
nervous system [19]. The reflexive increase in systemic
renin levels, responding to systemic Ang II inhibition,
stimulates Ang II generation within the central nervous
system leading to increased thirst, polydipsia and polyuria
[20]. This effect was not seen in humans. This may reflect
differences in amount of drug given or different pathways
for Ang II production in humans.
Fig. 1. Urinary citrate in rats. Twenty-four-hour urine collections were
made from control and enalapril-treated animals on day 7. (A) Total
urinary citrate excretion. (B) Fractional excretion of citrate. *P , 0.005.
Table 1. Urinary excretion in rats
Control Enalapril
Volume ml 7.5 6 0.9 15.3 6 2.0a
Na mEq/day 1.1 6 0.1 1.3 6 0.2
K mEq/day 0.43 6 0.04 0.60 6 0.06b
Cl mEq/day 1.3 6 0.1 1.6 6 0.2
Creatinine mg/day 6.1 6 0.4 6.9 6 0.8
Twenty-four-hour samples were obtained during day 7.
a P , 0.005
b P , 0.05
Table 2. Blood composition in rats
Control Enalapril
pH 7.43 6 0.01 7.40 6 0.01
pCO2 mm Hg 34.3 6 0.8 35.9 6 1.0
[HCO3] 23.7 6 0.5 23.2 6 1.1
[Na] 142 6 1 141 6 1
[K] 4.2 6 0.1 4.3 6 0.1
[Cl] 111 6 1 112 6 1
Creatinine mg/dl 0.38 6 0.02 0.45 6 0.04
Glucose mg/dl 191 6 3 182 6 6
Citrate mg/liter 49 6 4 48 6 6
Aortic blood punctures were performed on day 8.
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An adaptive increase in ATP citrate lyase activity, similar
to that seen in rats with metabolic acidosis and hypokale-
mia [10], likely contributes to the hypocitraturic effect of
enalapril. This ATP-dependent cytosolic enzyme cleaves
citrate to oxaloacetate and acetyl CoA. This provides the
cytosol with acetyl CoA needed for fatty acid synthesis. The
oxaloacetate generated enters the gluconeogenic pathway,
also up-regulated in CMA and hypokalemia, through phos-
phoenolpyruvate carboxykinase [11].
The hypocitraturia seen with angiotensin converting en-
zyme inhibitors, CMA, and hypokalemia is likely due to a
decrease in proximal tubule pHi. In the case of converting
enzyme inhibition, the decrease in pHi is likely due to
inhibition of Ang II-induced stimulation of the proximal
tubule apical membrane Na/H antiporter. This decrease in
pHi then leads to a series of adaptations resulting in
increased citrate absorption and hypocitraturia. Because
Ang II directly stimulates proximal tubular bicarbonate
absorption and ammoniagenesis, decreases in pHi associ-
ated with converting enzyme inhibition may not stimulate
these processes, as is seen in CMA and hypokalemia [21].
Administration of enalapril in typical pharmacological
doses to normal human volunteers resulted in a small but
significant decrease in both urine citrate excretion and
concentration. In order to minimize the dietary influences
on the urinary citrate excretion, we limited the dietary acid
ash content. Both urinary uric acid and sulfate excretions
were low and similar before and after enalapril, indicating
low dietary consumption of purine and net acid production,
respectively [22]. Similar to rats, the decrease in urinary
citrate in humans occurred in the absence of a decrease in
serum pH or potassium concentration. A number of possi-
ble explanations exist for the reason the effect on citrate
excretion was smaller in humans than in rats. First, we used
a smaller dose of enalapril in humans. Second, the differ-
ence in the amount and composition of protein in both
diets may affect urinary citrate in control values that would
be expected to modulate the magnitude of enalapril’s
effects [23]. Lastly, it is possible that Ang II has a smaller
effect on proximal tubule cell pHi in humans. In the
proximal tubule, Ang II stimulates Na/H antiporter which
increases pHi, and the Na/3HCO3 transporter which de-
creases pHi [13]. The relative magnitude of the effects of
these two transporters may be different between humans
and rats, resulting in different effects on proximal tubule
pHi.
A decrease in urinary citrate excretion occurring with
inhibition of Ang II synthesis may have significant clinical
implications. These agents may increase the incidence of
urolithiasis in certain patients. In addition, suppression of
Ang II synthesis may be responsible for hypocitraturia seen
in patients on a high salt diet [16], and Sakhaee et al
showed that a high salt diet causes a 20% decrease in total
urinary citrate excretion without affecting plasma pH or
potassium. Thus, a high salt diet and enalapril administra-
tion may decrease urinary citrate through a similar mech-
anism, decreases in Ang II levels.
In summary, these studies reveal that enalapril decreases
Fig. 2. Renal cortical ATP citrate lyase activity. Renal cortical tissue was
harvested from control and enalapril-treated animals. Enzyme activity was
measured spectrophotometrically (*P , 0.005).





Volume ml 2323 6 263 2419 6 260
pH 6.33 6 0.09 6.34 6 0.08
Na mEq/day 95 6 11 104 6 16
K mEq/day 43 6 6 42 6 5
Creatinine mg/day 1513 6 176 1434 6 168
Sulfate mg/day 17.4 6 1.4 18.8 6 2.2
Uric acid mg/day 567 6 41 576 6 40
NH4 mmol/day 34 6 3 36 6 4
Ca mg/day 150 6 10 149 6 13
Oxalate mg/day 29 6 2 27 6 2





Glucose mg/dl 80 6 3 82 6 2
BUN mg/dl 10 6 1 11 6 1
Creatinine mg/dl 0.9 6 0.04 1.0 6 0.04
[Na] 140 6 1 139 6 1
[K] 4.1 6 0.1 4.2 6 0.1
[Cl] 105 6 1 103 6 1
[total CO2] 26.4 6 0.9 27.8 6 1.1
Uric acid mg/dl 3.9 6 0.4 3.6 6 0.3
Phosphorus mg/dl 3.4 6 0.1 3.3 6 0.1
Cholesterol mg/dl 169 6 7 161 6 6a
iCalcium 4.0 6 0.1 4.1 6 0.1
pH 7.37 6 0.01 7.36 6 0.01
pCO2 mm Hg 49 6 1 50 6 2
a P , 0.05
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urinary citrate excretion in rats and humans. The mecha-
nism that mediates the hypocitraturia is similar to that
observed in animals with CMA and hypokalemia, and may
occur secondary to a decrease in renal proximal tubular
pHi. Furthermore, these studies suggest that angiotensin
converting enzyme inhibitors should be used with caution
in patients at risk for developing urolithiasis.
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